- tags:diabetic retinopathy
Research
Cholesterol medication may also reduce DR risk
LENS trial evaluated the cholesterol medication fenofibrate’s potential ability to slow DR.
Products
Eyedaptic introduces AI-powered smart glasses for AMD
Next-gen device features interactive, generative visual assistant with a built-in camera and hands-free capabilities.
Research
Prevalence of DR is increasing among diabetics, minorities
New study identifies trends in type 1 and type 2 diabetic retinopathy prevalence.
Research
Topcon and Orbis partner to expand DR screenings in sub-Saharan Africa
Collaboration utilizes robotic fundus imaging cameras and an AI-based platform that deliver results in mere seconds for Rwanda patients.
Products
SUSVIMO phase 3 data supports sustained efficacy for DR, DME
FDA has also accepted Genentech’s sBLA for the sustained-release drug delivery system’s diabetic eye disease indications.
Research
AAO, NANOS respond to study on semaglutide-NAION connection
Recent research identified substantial risk for NAION development among diabetic and obese patients using the GLP-1 RA.
Research
Semaglutide for diabetes tied to increased NAION risk
Mass Eye and Ear researchers identify higher incidence among patients taking popular weight loss and Type 2 diabetes drug.
Products
FDA approves EYLEA biosimilar for serious retinal diseases
Formycon reports the generic biosimilar demonstrates a comparable efficacy, safety, pharmacokinetics, and immunogenicity to Regeneron’s aflibercept.
Pipeline
Ocular Therapeutix releases positive NPDR phase 1 data, plans for wet AMD repeat dosing study
Updates follow company’s decision to cut 13% of workforce in order to focus on the clinical development of axitinib intravitreal implant.
Research
AAO validates teleretinal screening for effective DR detection
Teleretinal screening shown to be an accurate and cost-effective approach to DR screening.
Products
FDA approves first interchangeable aflibercept biosimilars
Generic equivalents to Eylea demonstrate a comparable quality, safety, and efficacy profile for wet AMD, DME, RVO, and DR.
Research
Study examines DME, PDR risk with popular diabetes drugs
GLP-1 agonists linked with a higher rate of progression to PDR and risk of new-onset DME.
Pipeline
EyePoint fails to meet primary goal in phase 2 NPDR trial
Interim 9-month data finds DURAVYU demonstrated a continued favorable safety profile and tolerability similar to its other indications for DME and wet AMD.
Research
Ocuphire releases post-hoc phase 2 data on DR oral supplement
Presented at ARVO, results from an analysis of the ZETA-1 trial demonstrate favorable safety and tolerability for oral supplementation.
Pipeline
Naegis Pharma secures financing to advance retinal disease candidate
Funding will support IND-application for phase 2 trial on investigational asset, which is designed to protect the retina and cornea from damage via oral administration.
Products
FDA clears first-ever fully autonomous AI portable DR screening
AEYE Health’s AEYE Diagnostic Screening is designed to detect diabetic retinopathy in adult patients in just 1 minute.
Research
Medical coverage rates makes a difference in PDR diagnosis
Study finds insurance type correlates to disease severity and increased downstream healthcare utilization.
Products
20/20NOW and Visionix partner on DR telehealth screening
Latest addition to the tele-optometry platform will be introduced during the 2024 American Telemedicine Association’s 2024 Nexus Conference and Expo in May.
Products
iHealthScreen receives US patent for iPredict glaucoma detection model
Screening system is also CE-certified to provide a fully automated screening for AMD via retinal imaging with instant results.
Research